SLC43A3: A Potential Drug Target for Neurological Disorders (G29015)

Target Name: SLC43A3

NCBI ID: G29015

SLC43A3

SLC43A3: A Potential Drug Target for Neurological Disorders

SLC43A3 (EEG1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various neurological disorders, including epilepsy, bipolar disorder, and schizophrenia. The study of SLC43A3 and its potential uses have generated a lot of interest in the scientific community.

SLC43A3 is a gene that encodes a protein known as solute carrier family 43 member 3. This protein is expressed in the brain and is involved in the transport of various substances, including neurotransmitters, across the blood-brain barrier. It is a transmembrane protein, which means that it spans the membrane of the brain and continues to the other side.

Research has shown that SLC43A3 is involved in the regulation of a variety of neural circuits, including those involved in mood, emotion, and learning. It has been shown to play a role in the development and progression of epilepsy, bipolar disorder, and schizophrenia.

One of the key features of SLC43A3 is its expression pattern in the brain. Studies have shown that people with epilepsy, bipolar disorder, and schizophrenia have reduced levels of SLC43A3 in certain parts of the brain, compared to healthy individuals. This suggests that these disorders may be associated with disruptions in the function of SLC43A3.

In addition to its potential involvement in neurological disorders, SLC43A3 has also been shown to be a potential biomarker for several of these disorders. For example, research has shown that people with epilepsy may have lower levels of SLC43A3 in their brain, which could be used as a biomarker for the disorder. Similarly, people with bipolar disorder and schizophrenia may have reduced levels of SLC43A3 in certain parts of the brain, which could be used as a biomarker for these disorders.

Another promising aspect of SLC43A3 is its potential as a drug target. Research has shown that SLC43A3 can be blocked with small molecules, which can reduce the activity of the protein and improve symptoms of epilepsy, bipolar disorder, and schizophrenia. This suggests that SLC43A3 may be an attractive target for new treatments for these disorders.

In conclusion, SLC43A3 is a gene that has been shown to be involved in the regulation of various neural circuits and has been associated with the development and progression of several neurological disorders. Its potential as a drug target or biomarker for these disorders makes it an attractive target for new treatments. Further research is needed to fully understand the role of SLC43A3 in neurological disorders and to develop safe and effective treatments.

Protein Name: Solute Carrier Family 43 Member 3

Functions: Sodium-independent purine-selective nucleobase transporter which mediates the equilibrative transport of extracellular purine nucleobases such as adenine, guanine and hypoxanthine (PubMed:26455426, PubMed:32339528). May regulate fatty acid (FA) transport in adipocytes, acting as a positive regulator of FA efflux and as a negative regulator of FA uptake (By similarity)

The "SLC43A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC43A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets